O
TECH icon

OrbiMed’s Bio-Techne TECH Stock Holding History

OrbiMed’s Portfolio TECH Stock Details TECH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-200,000
Closed -$4.73M – 146
2013
Q4 		$4.73M Sell
200,000
-864,000
-81% -$18.7M 0.07% 97
2013
Q3 		$21.3M Buy
1,064,000
+720,000
+209% +$13.7M 0.38% 55
2013
Q2 		$5.94M Buy
+344,000
New +$5.71M 0.13% 97

Other funds holding TECH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $10.9B AUM 27.5% 1-Year Est. Return

OrbiMed's TECH Position: Q1 2014 in Review

OrbiMed sold out of Bio-Techne (TECH) in Q1 2014, closing a stake of 200,000 shares — an estimated $4.73M sold.

OrbiMed first reported a position in TECH in Q2 2013 and held it in 3 quarters. The position peaked at $21.3M in Q3 2013. 240 funds tracked by Wall St. Rank hold TECH as of Q1 2014.

  • OrbiMed reported no remaining Bio-Techne position as of Q1 2014 after selling out during the quarter.
  • OrbiMed sold 200,000 Bio-Techne shares in Q1 2014, an estimated $4.73M.
  • OrbiMed first reported a position in Bio-Techne in Q2 2013 and held it in 3 quarters.
  • OrbiMed's Bio-Techne position peaked at $21.3M in Q3 2013.
  • 240 funds tracked by Wall St. Rank held Bio-Techne as of Q1 2014.

Based on OrbiMed's 13F filing for Q1 2014, filed 15 May 2014.